Janssen Asperger's MRS Risperidone Study

This study has been completed.
Sponsor:
Collaborator:
Ortho-McNeil Janssen Scientific Affairs, LLC
Information provided by:
Georgia Regents University
ClinicalTrials.gov Identifier:
NCT00352196
First received: July 12, 2006
Last updated: July 19, 2011
Last verified: July 2011
  Purpose

This study will be an open-label, 12-week trial of risperidone in subjects with Asperger's Disorder, according to DSM-IV Criteria. The study has two arms, one involving pre- and post-treatment MRS studies, and one without MRS. The MRS arm will study 18-20 subjects ages 6 and above, with a target of 14 completing patients. For both arms, we plan to a enroll at total of 30 patients to achieve completion for 24 patients. The non-MRS arm of the study will include subjects 6-18 years of age, the bulk of which have completed the study as of the writing of this updated revision. Our hypotheses are that treatment of Asperger's patients with a low dose of risperidone will:

  1. decrease ratios of N-acetylaspartate (NAA), creatine, phosphocreatine (Cr + PCr), and choline in the prefrontal lobe, and
  2. decrease the severity of negative symptoms and overall improve social behavior, and
  3. that the two will be correlated.

Specific Aims

The primary objectives of this trial are to:

  • Further assess and investigate the utility of risperidone in the treatment Asperger's disorder.
  • Assess the efficacy of risperidone in normalizing increased frontal lobe metabolites.
  • Assess the efficacy of risperidone in normalizing symptoms in Asperger's disorder patients using standardized rating scales to assess the impact on negative symptoms and on social interaction.
  • Determine whether risperidone's effect on clinical improvement of Asperger's disorder, i.e., negative symptoms, is correlated with normalization of frontal lobe metabolites
  • Accrue safety and tolerability data on risperidone for this population of patients.

This information could potentially be used to provide pilot data for a double blind trial


Condition Intervention Phase
Asperger's Disorder
Drug: risperidone
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Biological Basis of Therapy for Negative Symptom Spectrum Disorders: Risperdal Effect on Frontal Metabolism in Asperger's Disorder

Resource links provided by NLM:


Further study details as provided by Georgia Regents University:

Primary Outcome Measures:
  • Scale for the Assessment of Negative Symptoms (SANS)

Secondary Outcome Measures:
  • PANNS - Positive and Negative Symptom Scale
  • BPRS - Brief Psychiatric Rating Scale
  • MADRS - Montgomery Asberg Rating Scale
  • GAS - Global Assessment Scale
  • AIMS - Abnormal Involuntary Movement Scale
  • Neurocognitive test battery

Enrollment: 23
Study Start Date: November 2001
Study Completion Date: September 2008
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must be age 6 -18 for the Non-MRS arm of the study, and age 6 or above for the MRS arm of the study.
  2. If applicable, a parent or legal guardian or legal representatives of study subject must provide informed consent and sign an informed consent document.
  3. Female patients of childbearing age must be either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practicing an acceptable method of contraception (oral or parenteral hormonal contraceptives, intrauterine device; barrier and spermicide. Abstinence is not an acceptable method).
  4. Female patients of child-bearing potential must have a negative pregnancy test to be performed at screening and baseline.
  5. Patients must meet DSM-IV criteria for Asperger's Disorder. Other Axis I & II disorders excluded are listed below.
  6. Patient must not have other serious, unstable illnesses and must be otherwise physically healthy on the basis of a physical examination, medical history, electrocardiogram and the results of blood biochemistry, hematology tests and a urinalysis.
  7. Patient must have a negative urine drug screen with the exception of amphetamines if the patient is being treated with stimulants for four months or longer prior to entry.

Exclusion Criteria:

  1. Patients who meet DSM-IV criteria for any psychotic disorder including schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, psychotic disorder due to a general medical condition, substance-induced psychotic disorder,psychotic disorder not otherwise specified, major depression with psychotic features, or bipolar disorder.
  2. Patients who meet DSM-IV criteria for schizoid, schizotypal, or paranoid personality disorder. Patients who meet DSM-IV criteria for autistic disorder or pervasive developmental disorder.
  3. Claustrophobic patients and those otherwise unable to successfully complete the MRS procedure prior to baseline.
  4. Patients who meet criteria for substance abuse or dependence within the past three months. (Nicotine and caffeine are exceptions).
  5. Patients believed by the investigator to be at significant risk for suicidal or violent behavior during the course of the trial.
  6. Female patients who are pregnant or nursing.
  7. Patients with a known or suspected seizure disorder.
  8. If the results of the serum ALT or AST are more than twice the upper limit of the central laboratory's reference range, the patient may not be enrolled. If the results of any other biochemistry, hematology or urinalysis tests are not within the central laboratory's reference ranges, the patient can be enrolled only on condition that the investigator judges that the deviations are not clinically significant. This should be clearly recorded on the laboratory report and in the source documents.
  9. Patients with a history of neuroleptic malignant syndrome (NMS) or similar encephalopathic syndrome.
  10. Patients who, by history, have received treatment with Risperdal or another neuroleptic (including olanzapine or quetiapine) within three months of baseline evaluation. Patients who have received a depot antipsychotic within one treatment cycle prior to screening. Patients who have taken an antidepressant, or lithium within 4 weeks of the trial, 6 weeks for fluoxetine. Patients who have taken any psychotropic medication within 1 week of the trial. Patients who require concomitant medications during the trial.
  11. Patients with a suspected history of hypersensitivity or intolerance to risperidone.
  12. Patients with a known or suspected history of severe drug allergy or hypersensitivity (e.g., Steven Johnson's syndrome)
  13. Patients with an anticipated life expectancy of six months or less.

    -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00352196

Locations
United States, Georgia
Medical College of Georgia, Dept. of Psychiatry
Augusta, Georgia, United States, 30912-3800
Sponsors and Collaborators
Georgia Regents University
Ortho-McNeil Janssen Scientific Affairs, LLC
Investigators
Principal Investigator: Jeffrey L Rausch, MD Georgia Regents University
Study Director: Donna L Londino, MD Georgia Regents University
  More Information

No publications provided

Responsible Party: Dr. Donna Londino, Georgia Health Sciences University
ClinicalTrials.gov Identifier: NCT00352196     History of Changes
Other Study ID Numbers: RIS-EMR-4026, MCG HAC File #01-09-063
Study First Received: July 12, 2006
Last Updated: July 19, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Georgia Regents University:
Asperger's Disorder
Risperidone
Magnetic Resonance Spectroscopy
Social Skills

Additional relevant MeSH terms:
Asperger Syndrome
Child Development Disorders, Pervasive
Mental Disorders Diagnosed in Childhood
Mental Disorders
Risperidone
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents

ClinicalTrials.gov processed this record on July 23, 2014